TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02759029

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eradication of Helicobacter pylori
Description: clarithromycin-based triple therapy Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk~* concomitant therapy group Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk Metronidazole 500mg, PO, BID, 1wk~* bismuth based quadraple therapy Pantoloc 40mg, PO, BID, 1wk Bismuth, 300mg, PO, QID, 1wk Tetracycline, 500mg, PO, QID, 1wk Metronidazole, 500mg, PO, TID, 1wk~* levofloxacine based triple therapy Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Levofloxacin 500mg, PO, QD, 1wk

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: eradication of Helicobacter pylori
Description: clarithromycin-based triple therapy Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk~* concomitant therapy group Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk Metronidazole 500mg, PO, BID, 1wk~* bismuth based quadraple therapy Pantoloc 40mg, PO, BID, 1wk Bismuth, 300mg, PO, QID, 1wk Tetracycline, 500mg, PO, QID, 1wk Metronidazole, 500mg, PO, TID, 1wk~* levofloxacine based triple therapy Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Levofloxacin 500mg, PO, QD, 1wk
Study: NCT03314584

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Magnetic resonance imaging (MRI)
Description: Brain imaging will be done via MRI prior to the first rTMS/Sham TMS session. Imaging will allow investigators to target specific areas in the brain.
Study: NCT02759029

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: eradication of Helicobacter pylori
Description: clarithromycin-based triple therapy Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk~* concomitant therapy group Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk Metronidazole 500mg, PO, BID, 1wk~* bismuth based quadraple therapy Pantoloc 40mg, PO, BID, 1wk Bismuth, 300mg, PO, QID, 1wk Tetracycline, 500mg, PO, QID, 1wk Metronidazole, 500mg, PO, TID, 1wk~* levofloxacine based triple therapy Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Levofloxacin 500mg, PO, QD, 1wk
Study: NCT02672813

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pectoral nerve I and II block
Description: Under Ultrasound guidance, Pectoral nerve I and II block is given for every breast surgery by using 10 and 20 ml of 0.25% Ropivacaine respectively
Study: NCT03543839

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Belimumab
Description: Subjects in this arm will receive 200mg belimumab subcutaneously weekly for 2 years

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belimumab/Placebo
Description: Subjects in this arm will receive weekly subcutaneous injections of 200mg belimumab for 1 year and then placebo subcutaneous injections for 1 year.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in this arm will receive weekly subcutaneous injections of placebo for 2 years
Study: NCT00673296

Intervention type: DRUG
Group type: OTHER
Intervention: Intravitreal Bevacizumab
Description: Intravitreal injection of bevacizumab (1.25 mg in 0.05 mL) and C3F8 (0.2-0.3 mL)
Study: NCT00731211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: 800 mg of pazopanib orally each day continuously
Study: NCT02550262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 0.0625% Bupivacaine plus fentanyl 2mcg/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 0.0625% Bupivacaine plus fentanyl 2mcg/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 0.0625% Bupivacaine plus fentanyl 2mcg/ml
Study: NCT03429855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: trunk training
Description: Bobath based trunk training

Intervention type: OTHER
Group type: OTHER
Intervention: physiotherapy
Description: conventional physiotherapy
Study: NCT04018118

Intervention type: BIOLOGICAL
Intervention: Biological sample
Description: Additional blood samples for biobanking
Study: NCT03603717

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: The intervention will consist of a standard, structured, multi-component intervention for insomnia that includes sleep education, sleep hygiene, sleep restriction, stimulus control, and cognitive therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene
Description: The intervention will include basic psychoeducation about sleep, discussion of sleep hygiene factors that disrupt and improve sleep, setting sleep hygiene goals, and developing action steps to achieve those goals.
Study: NCT01670110

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pasireotide LAR
Description: Injectible, 60mg per month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: To be injected once per month
Study: NCT02741167

Intervention type: PROCEDURE
Intervention: CRS and HIPEC
Description: During CRS, all visible peritoneal tumors are removed. Consequently micrometastasis are removed with hyperthermic intraperitoneal chemotherapy
Study: NCT03438487

Intervention type: BIOLOGICAL
Intervention: Flucelvax Trivalent Influenza Vaccine
Description: Flucelvax is a cell culture seasonal trivalent influenza vaccine that contains the following influenza hemagglutinin antigens: 1) A/H1N1-like virus, 2) A/(H3N2)-like virus, 3) B/Yamagata lineage or B/Victoria lineage~Vaccine exposure in routine care (no vaccination per protocol)

Intervention type: BIOLOGICAL
Intervention: Flucelvax Quadrivalent Influenza Vaccine
Description: Flucelvax Quadrivalent is a cell culture seasonal quadrivalent influenza vaccine that contains the following influenza hemagglutinin antigens: 1) A/H1N1-like virus, 2) A/(H3N2)-like virus, 3) B/Yamagata lineage, 4) B/Victoria lineage~Vaccine exposure in routine care (no vaccination per protocol)
Study: NCT02841891

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sylys® Surgical Sealant
Description: Standard Stapled Anastomosis Colectomy Procedure with the addition of Sylys® Surgical Sealant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stapled Anastomosis Colectomy Procedure
Description: Standard Stapled Anastomosis Colectomy Procedure without the addition of Sylys® Surgical Sealant
Study: NCT01372163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05190457 or Placebo
Description: Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05190457 or Placebo
Description: Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05190457 or Placebo
Description: Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05190457 or Placebo
Description: Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05190457 or Placebo
Description: Once daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast in healthy volunteers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05190457 or Placebo
Description: Once daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast in healthy volunteers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05190457 or Placebo
Description: Once (or twice) daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast (and dinner if twice) in Type 2 Diabetic patients.
Study: NCT00966199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-hypertensive medication
Description: 8-12 weeks of anti-hypertensive treatment with 2 weekly titration using registered hypertensive medication
Study: NCT02279342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: The starting dose of the febuxostat will be 10mg /day. The dose will be increased to 20 mg/day at week 4 and finally titrated to 40 mg/day at week 8.
Study: NCT01560949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 75 mg/m2 by vein on Day 1 of weeks 1, 3, 5, 7, 9 and 11 for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 150 mg/m2 by vein on Day 1 of weeks 1, 3, 5, 7, 9 and 11 for 12 weeks.
Study: NCT03499951

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wheelchair Skills Training - Remote
Description: Individuals will receive wheelchair skills training remotely. They will be provided with the Wheelchair Skills Training Program to review (http://www.wheelchairskillsprogram.ca/eng/index.php), and then will be directed to use this information to perform the wheelchair skills. They will video the attempts, and will receive feedback on methods to improve their techniques.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wheelchair Skills Training - In Person
Description: Individuals will receive wheelchair skills training in one-on-one sessions, taught by those who received the wheelchair skills training remotely.
Study: NCT03807739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0134 F09 Formulation
Description: Participants will receive a single oral dose of GDC-0134 reference capsule F09.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0134 F09 Formulation
Description: Participants will receive a single oral dose of GDC-0134 reference capsule F09.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0134 F15 Formulation
Description: Participants will receive a single oral dose of GDC-0134 prototype capsule F15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0134 F16 Formulation
Description: Participants will receive a single oral dose of GDC-0134 prototype capsule F16.
Study: NCT00875017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum Carbonate
Description: 1 x 1000mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer
Description: 3 x 800mg tablets
Study: NCT02550262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 0.0625% Bupivacaine plus fentanyl 2mcg/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 0.0625% Bupivacaine plus fentanyl 2mcg/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 0.0625% Bupivacaine plus fentanyl 2mcg/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 0.0625% Bupivacaine plus fentanyl 2mcg/ml

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infusion pump
Description: Infusion pump set to deliver programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infusion pump
Description: Infusion pump set to deliver programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infusion pump
Description: Infusion pump set to deliver programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA).
Study: NCT01560949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 2000 mg/m2 by vein over 46 hour continuous infusion, on Days 1 - 2 during weeks 1, 3, 5, 7, 9 and 11 for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 350 mg/m2 by vein every week for 5 doses beginning Day 1 (days 1, 8, 15, 22, 29).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: External beam radiation therapy delivered 5 days/week +/- 2 days over 5.5 weeks with 18-MeV photons. 3D conformal RT, a total dose of 50.4 Gy 1.8 Gy/fraction (28 fractions).
Study: NCT02132702

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ekso
Study: NCT02550262

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infusion pump
Description: Infusion pump set to deliver programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA).
Study: NCT02833350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0853
Description: Participants will receive GDC-0853 at low, mid, or high doses, orally once or twice daily for 12 weeks in Cohort 1 or 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0853
Description: Participants will receive GDC-0853 at low, mid, or high doses, orally once or twice daily for 12 weeks in Cohort 1 or 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0853
Description: Participants will receive GDC-0853 at low, mid, or high doses, orally once or twice daily for 12 weeks in Cohort 1 or 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0853
Description: Participants will receive GDC-0853 at low, mid, or high doses, orally once or twice daily for 12 weeks in Cohort 1 or 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Participants will receive adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks.
Study: NCT01996735

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 180 mg single dose
Study: NCT02730767

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: partially supervised exercise intervention
Study: NCT02043717

Intervention type: DIETARY_SUPPLEMENT
Intervention: Vitamin D
Description: Supplementing oral cholecalciferol according to the new guidelines by:~Tangpricha V, Kelly a, Stephenson a, Maguiness K, Enders J, Robinson K a, et al. An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation. The Journal of clinical endocrinology and metabolism \[Internet\]. 2012 May \[cited 2012 Oct 31\];97(4):1082-93. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22399505
Study: NCT04231474

Intervention type: DEVICE
Intervention: Urodynamic testing
Description: All data were obtained using the MMS Alfa 4T by the same urologist with use of an 8 Charr catheter.
Study: NCT01996735

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05187806

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational interview
Description: After the pretest, the experimental group was intervened with a motivational interview (MI) method that consisted of four sessions.The pretest and posttest Diabetes Self-Management Scale total scores and HbA1c values of the patients in the experimental and control groups were compared.
Study: NCT02238028

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wear respirator
Description: Healthy adult subjects wore the particulate filtering respirators for continuous 48 hours as much as possible both indoor and outdoor.
Study: NCT01303835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDN
Description: Randomized patients received 4.5 mg low dose naltrexone (LDN) to be taken every night before bed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomized patients received placebo to be taken every night before bed.
Study: NCT03067051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verteporfin
Description: In the last decade a clinical interest of developing new methods for minimally invasive treatments of organ-confined prostatic malignancies has been pursued. In this study the drug verteporfin for injection (VFI) is to be used with the SpectraCure P18 System (Interstitial multiple diode lasers and IDOSE® Software).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpectraCure P18 System
Description: Interstitial Photodynamic therapy is provided with the the SpectraCure P18 system
Study: NCT04183166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG4050
Description: Subcutaneous injections weekly for the first 6 weeks and then every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG4050
Description: Subcutaneous injections weekly for the first 6 weeks and then every 3 weeks
Study: NCT02299921

Intervention type: OTHER
Intervention: Characterize alcohol and drug use
Description: Characterize alcohol and drug use in patients newly admitted to the medical ICU service, who are expected to stay in the ICU for greater than 48 hours. The investigators will collect blood, exhaled breath condensate, urine and hair samples over the first 10 days of hospitalization. A select subset of subjects will have bronchoalveolar lavage (BAL) obtained.

Intervention type: OTHER
Intervention: Characterize alcohol and drug use
Description: Characterize alcohol and drug use in patients newly admitted to the medical ICU service, who are expected to stay in the ICU for greater than 48 hours. The investigators will collect blood, exhaled breath condensate, urine and hair samples over the first 10 days of hospitalization. A select subset of subjects will have bronchoalveolar lavage (BAL) obtained.
Study: NCT04544995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered as TfOS (Tablet for oral suspension)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered as TfOS (Tablet for oral suspension)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered as TfOS (Tablet for oral suspension)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered as TfOS (Tablet for oral suspension)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered as TfOS (Tablet for oral suspension)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered as IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered as IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered as IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered as IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered as IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered as tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered as tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered as tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered as tablet
Study: NCT03657680

Intervention type: OTHER
Intervention: Evaluation
Description: The volunteers were submitted to an evaluation of pain, range of motion, muscular strength and functional capacity.
Study: NCT04544995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered as tablet
Study: NCT03913624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Study: NCT04674709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo group receives 4 doses of placebo in a 24-hour period for a period of 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group receives 4 doses of placebo in a 24-hour period for a period of 7 days
Study: NCT01139385

Intervention type: PROCEDURE
Intervention: Harmonic scalpel
Description: The Cholecystectomy is performed using only Harmonic Scalpel to mobilize the Cholecystis and to close the cystic duct and the cystic artery
Study: NCT02833350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Participants will receive stable background therapy of folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
Study: NCT03134235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Subjects consumed a raw, vegan diet for 4-weeks with an emphasis on raw fruit and vegetable consumption.
Study: NCT02165059

Intervention type: PROCEDURE
Intervention: Surgical Full Thickness Biopsy
Description: Eligible subjects will undergo a surgical full thickness biopsy of the stomach and/or proximal jejunum as part of their planned surgery.

Intervention type: PROCEDURE
Intervention: Surgical Full Thickness Biopsy
Description: Eligible subjects will undergo a surgical full thickness biopsy of the stomach and/or proximal jejunum as part of their planned surgery.
Study: NCT01139385

Intervention type: PROCEDURE
Intervention: Traditional
Description: The cholecystectomy is performed using Harmonic Scalpel to mobilize the cholecystis and the cystic duct and the cystic artery are closed by titanium clips
Study: NCT04065230

Intervention type: DRUG
Intervention: Tenofovir Alafenamide Fumarate tablets
Description: Eligible hepatitis B pregnant women are given TAF antiviral therapy (25mg, oral, 1/day) at 24-28 weeks of gestation until one month after delivery.
Study: NCT00788515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volinanserin (M100907)
Description: 2 mg tablets QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lormetazepam
Description: 1 mg tablets (overencapsulated) QD
Study: NCT02773719

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: True Biofield therapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fake Biofield therapy
Study: NCT00861484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK958108
Description: Coated Tablets 1 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Coated tablets
Study: NCT03330899

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H7N9 antigen + adjuvant IB160
Description: H7N9 monovalent (fragmented and inactivated)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H7N9 antigen + adjuvant IB160
Description: H7N9 monovalent (fragmented and inactivated)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H7N9 antigen + adjuvant IB160
Description: H7N9 monovalent (fragmented and inactivated)